摘要
Abstract
Objective To evaluate the ticagrelor treatment of percutaneous coronary intervention in patients with the clinical effects of clopidogrel resistance. Methods In our hospital percutaneous coronary intervention in patients with 80 cases, patients were selected by the TEG (thrombelastograph) were confirmed as clopidogrel resistance. By randomly selected cases will be divided into experimental and control groups with 40 patients in the control group continued clopidogrel therapy(75 mg / d, for 7 d), the experimental group received ticagrelor therapy (90 mg, 2 times / d, for 7 d), aspirin(100 mg, 1 times / d), for 3 weeks, follow - up 3 months. Results Platelet count was (198. 21 ± 86. 62) × 109 / L, platelet aggregation rate (44. 51 ± 8. 65)% , adenosine diphosphate maximum aggregate time (63. 21 ± 56. 21 ) s, the maximum aggregate rate of adenosine diphosphate It was (35. 61 ± 6. 95)% , and the control group (188. 54 ± 83. 62) × 109 / L, (36. 32 ± 5. 63)% , (178. 51 ± 89. 65) s, (65. 12 ± 8. 21)% , the difference was statistically significant( P < 0. 05) . Experimental cardiovascular events was 5. 00% , significantly lower than the 22. 50% in the control group( P < 0. 05); the experimental group, bleed-ing was 2. 50% , down from 10. 00% in the control group, but no significant difference between groups( P > 0. 05) . Conclusion Tica-grelor therapy after percutaneous coronary intervention in patients with clopidogrel resistance results were satisfactory, safe, large hospitals at all levels learn applications.关键词
替格瑞洛/氯吡格雷抵抗/冠状动脉介入Key words
ticagrelor/clopidogrel/coronary intervention分类
医药卫生
